The world-famous vaccine maker Moderna (NASDAQ: MRNA) will report its third-quarter earnings on Nov. 4 before the market opens, and that means savvy investors are already planning for what to do after getting the new information. In the second quarter, the biotech reported that its quarterly revenue had grown by more than 6,398% year over year, so its Q3 results have a hard act to follow, to say the least. The key will be how its sales and manufacturing operations will shift in response to the anticipated need to make and deliver booster shots, which the Food and Drug Administration's (FDA) advisory committee recently unanimously voted to support.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting